Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 3;31(3):878-881.
doi: 10.1093/ibd/izae164.

Risankizumab Is Effective for The Management of Crohn's Disease of the Pouch

Maia Kayal  1 , Elizabeth A Spencer  2 , Matthew Smyth  2 , Laura Raffals  3 , Taha Qazi  4 , Parakkal Deepak  5 , Poonam Beniwal-Patel  6 , Shannon Chang  7 , Peter Higgins  8 , Raymond K Cross  9 , Chelsea Anderson  10 , Millie Long  10   11 , Hans H Herfarth  10   11 , Marla C Dubinsky  2 , Edward L Barnes  10   11
Affiliations

Risankizumab Is Effective for The Management of Crohn's Disease of the Pouch

Maia Kayal et al. Inflamm Bowel Dis. .
No abstract available

Plain language summary

In this prospective, multicenter observational study of highly refractory patients with Crohn’s disease of the pouch, risankizumab achieved the primary outcome of clinical remission in 50% and the more stringent secondary outcome of antibiotic- and steroid-free remission in 30.8% at 12 weeks.

PubMed Disclaimer

Conflict of interest statement

M.K. has served as a consultant or received advisory board fees from AbbVie, Pfizer, BMS, Jannsen, Fresenius Kabi.

P.D. has served as a consultant or on an advisory board for Janssen, Pfizer,

Prometheus Biosciences, Boehringer Ingelheim, AbbVie, Arena Pharmaceuticals and Scipher Medicine Corporation. He has also received funding under a sponsored research agreement unrelated to the data in the paper from Takeda Pharmaceutical, Arena Pharmaceuticals, Bristol

Myers Squibb-Celgene, and Boehringer Ingelheim.

P.B-P. has received honorarium from the Takeda speaker’s bureau.

M.D. has served as a consultant or has received advisory board fees from Abbvie, Arena, BMS, Eli Lilly, Gilead, Janssen, Pfizer, Prometheus Labs, Takeda. She has received grant support from Janssen, Abbvie. She also has the following relationships: Licenser of software: Takeda; Co-Founder, Equity ownership and board of director for Trellus Health

S.C. has served as a consultant for AbbVie, BMS, and Pfizer.

R.K.C. has participated in advisory boards and consulting for AbbVie, Adiso, Bristol Myers Squibb, Fresenius Kabi, Fzata, Janssen, Magellan Health, Option Care, Pharmacosmos, Pfizer, Samsung Bioepis, Sandoz, and Takeda and has a research grant with Janssen. He is an Executive Committee Member for the IBD Education Group and is Scientific Co-Director for the CorEvitas Registry.

M.D.L. has served as a consultant for AbbVie, UCB, Takeda, Janssen, Pfizer, Salix, Valeant, Target Pharmasolutions and has received research support from Pfizer and Takeda.

H.H.H. has served as a consultant for Alivio, BMS, Boehringer, ExeGi Pharma, Finch, Fresenius Kabi, Galapagos, Gilead, Janssen, Otsuka, Pfizer, Pure Tech, Ventyx and receibed research support from Allakos, Artizan, NovoNordisk, Pfizer.

E.L.B. has served as a consultant for AbbVie.

All other authors have no relevant disclosures.

Figures

Figure 1.
Figure 1.
Clinical and endoscopic PDAI subscore trend from baseline to 12 weeks.
See this image and copyright information in PMC

Comment in

References

    1. Barnes EL, Kochar B, Jessup HR, Herfarth HH.. The incidence and definition of Crohn’s disease of the pouch: a systematic review and meta-analysis. Inflamm Bowel Dis. 2019;25(9):1474-1480. doi: https://doi.org/ 10.1093/ibd/izz005 - DOI - PMC - PubMed
    1. Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ.. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018;16(3):343-356.e3. doi: https://doi.org/ 10.1016/j.cgh.2017.06.016 - DOI - PMC - PubMed
    1. Barnes EL, Agrawal M, Syal G, et al. ; AGA Clinical Guidelines Committee. Electronic address: clinicalpractice@gastro.org. AGA clinical practice guideline on the management of pouchitis and inflammatory pouch disorders. Gastroenterology. 2024;166(1):59-85. doi: https://doi.org/ 10.1053/j.gastro.2023.10.015 - DOI - PMC - PubMed
    1. Kayal M, Deepak P, Beniwal-Patel P, et al. Changes in therapy are not associated with increased remission in patients with Crohn’s disease of the pouch. Am J Gastroenterol. 2024;119(3):584-587. doi: https://doi.org/ 10.14309/ajg.0000000000002599 - DOI - PMC - PubMed
    1. Barnes EL, Deepak P, Beniwal-Patel P, et al. Treatment patterns and standardized outcome assessments among patients with Inflammatory conditions of the pouch in a prospective multicenter registry. Crohns Colitis 360. 2022;4(3):otac030. doi: https://doi.org/ 10.1093/crocol/otac030 - DOI - PMC - PubMed